Since diabetic platelets are characterized by an enhanced turnover rate, it may be
hypothesized that an increase in the frequency, rather than the dose, of drug administration
may be a more effective strategy to inhibit platelet reactivity in diabetic patients as this
may enable COX-1 blockade of newly generated platelets. However, how different dosing
regimens impact the pharmacodynamic effects of aspirin selectively in diabetes mellitus has
been poorly explored. Therefore, the aim of the present pilot investigation was to evaluate
how increasing the frequency of aspirin administration, remaining within the daily
recommended therapeutic doses, affects antiplatelet responsiveness in diabetic patients with
coronary artery disease.